Australia
Name: HavaH Therapeutics
Slogan: Developing prevention and early treatment options for hormonally driven breast cancer and other breast diseases.
Description: HavaH’s mission is to develop therapies with reduced side effects and early prevention of breast cancers including hormonal refractory ER+ breast cancer and metastatic cancer. Havah uses targeted modulation of the hormonal balance in the breast to achieve a more nuanced hormonal regulation than traditional hormonal therapies. HavaH is developing innovative, proprietary hormonal therapies that aim to improve quality of life for women globally. The company brings together a world-class team passionate about helping women live lives free from the suffering caused by breast pain, debilitating menopausal symptoms, and breast cancer. Havah has extensive clinical experience with T+Ai™ having generated data from more than 1,000 Australian women with breast disease through an ongoing open-label cohort study, with critical safety pharmacokinetic and early efficacy data already demonstrated.
Founded: 2006
Industries: Biotechnology, Health Care, Pharmaceutical
Headquarter: Australia
Last Investment: $1.00M Seed Round investment at 01 October 2006
Last Investment Investors: N/A
In summary, HavaH Therapeutics, based in Australia, aims to pioneer advanced therapies for breast diseases, with a focus on hormonally driven breast cancer. Established in 2006, the company has garnered clinical experience and recently secured a $1.00M investment in a Seed Round, showcasing potential for growth and impact in the biotechnology and healthcare industries.
